{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphoma&page=23&q=Hodgkin", "query": { "q": "Hodgkin", "condition": "Lymphoma", "page": 23 }, "page_size": 10 }, "pagination": { "page": 23, "page_size": 10, "total_count": 3806, "total_pages": 381, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphoma&page=24&q=Hodgkin&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphoma&page=22&q=Hodgkin&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-15T12:15:37.331Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00005811", "title": "Topotecan Hydrochloride in Treating Children With Meningeal Cancer That Has Not Responded to Previous Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "AIDS-related Diffuse Large Cell Lymphoma", "AIDS-related Diffuse Mixed Cell Lymphoma", "AIDS-related Diffuse Small Cleaved Cell Lymphoma", "AIDS-related Immunoblastic Large Cell Lymphoma", "AIDS-related Lymphoblastic Lymphoma", "AIDS-related Peripheral/Systemic Lymphoma", "AIDS-related Primary CNS Lymphoma", "AIDS-related Small Noncleaved Cell Lymphoma", "Childhood Diffuse Large Cell Lymphoma", "Childhood Immunoblastic Large Cell Lymphoma", "HIV-associated Hodgkin Lymphoma", "Leptomeningeal Metastases", "Recurrent Childhood Acute Lymphoblastic Leukemia", "Recurrent Childhood Acute Myeloid Leukemia", "Recurrent Childhood Large Cell Lymphoma", "Recurrent Childhood Lymphoblastic Lymphoma", "Recurrent Childhood Medulloblastoma", "Recurrent Childhood Small Noncleaved Cell Lymphoma", "Recurrent/Refractory Childhood Hodgkin Lymphoma", "Unspecified Childhood Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "topotecan hydrochloride", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Year to 21 Years" }, "enrollment_count": 77, "start_date": "2000-04", "completion_date": "2009-02", "has_results": false, "last_update_posted_date": "2013-02-21", "last_synced_at": "2026-10-15T12:15:37.331Z", "location_count": 1, "location_summary": "Arcadia, California", "locations": [ { "city": "Arcadia", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00005811" }, { "nct_id": "NCT00671034", "title": "Calaspargase Pegol or Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acute Lymphoblastic Leukemia", "Adult B Acute Lymphoblastic Leukemia", "Childhood B Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "Calaspargase Pegol-mknl", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Daunorubicin Hydrochloride", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Mercaptopurine", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Pegaspargase", "type": "DRUG" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Thioguanine", "type": "DRUG" }, { "name": "Vincristine Sulfate", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER", "RADIATION" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "30 Years", "sex": "ALL", "summary": "2 Years to 30 Years" }, "enrollment_count": 166, "start_date": "2008-07-21", "completion_date": "2021-03-31", "has_results": true, "last_update_posted_date": "2021-04-27", "last_synced_at": "2026-10-15T12:15:37.331Z", "location_count": 27, "location_summary": "Birmingham, Alabama • Orange, California • Palo Alto, California + 22 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Orange", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Farmington", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT00671034" }, { "nct_id": "NCT00243087", "title": "Investigation of Safety, Tolerability and Maximum Tolerated Dose (MTD) of BI 2536 in Patients With Recurrent Advanced Aggressive Non-Hodgkin's Lymphoma (NHL)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "BI 2536", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 41, "start_date": "2005-07", "completion_date": null, "has_results": false, "last_update_posted_date": "2024-12-20", "last_synced_at": "2026-10-15T12:15:37.331Z", "location_count": 4, "location_summary": "Washington D.C., District of Columbia • Omaha, Nebraska • Rochester, New York + 1 more", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "Rochester", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00243087" }, { "nct_id": "NCT04224493", "title": "A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Relapsed/Refractory Follicular Lymphoma", "Follicular Lymphoma", "Refractory Follicular Lymphoma" ], "interventions": [ { "name": "Tazemetostat", "type": "DRUG" }, { "name": "Placebo oral tablet", "type": "DRUG" }, { "name": "Lenalidomide", "type": "COMBINATION_PRODUCT" }, { "name": "Rituximab", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "DRUG", "COMBINATION_PRODUCT" ], "sponsor": "Epizyme, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 599, "start_date": "2020-06-11", "completion_date": "2029-03-01", "has_results": false, "last_update_posted_date": "2026-10-05", "last_synced_at": "2026-10-15T12:15:37.331Z", "location_count": 57, "location_summary": "Mobile, Alabama • Tucson, Arizona • Cerritos, California + 47 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Cerritos", "state": "California" }, { "city": "Clovis", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04224493" }, { "nct_id": "NCT01476787", "title": "Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Follicular Lymphoma" ], "interventions": [ { "name": "Rituximab", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Rituximab-CHOP", "type": "DRUG" }, { "name": "Rituximab-CVP", "type": "DRUG" }, { "name": "Rituximab-Bendamustine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1030, "start_date": "2011-12-29", "completion_date": "2024-04-30", "has_results": true, "last_update_posted_date": "2025-05-14", "last_synced_at": "2026-10-15T12:15:37.331Z", "location_count": 26, "location_summary": "Chandler, Arizona • Fullerton, California • Los Angeles, California + 21 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Fullerton", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Colorado Springs", "state": "Colorado" }, { "city": "Englewood", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01476787" }, { "nct_id": "NCT00003887", "title": "Lymphocyte Infusion in Treating Patients With Relapsed Cancer After Bone Marrow or Peripheral Stem Cell Transplantation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "Chronic Myeloproliferative Disorders", "Gestational Trophoblastic Tumor", "Kidney Cancer", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Neuroblastoma", "Ovarian Cancer", "Sarcoma", "Testicular Germ Cell Tumor" ], "interventions": [ { "name": "peripheral blood lymphocyte therapy", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "70 Years", "sex": "ALL", "summary": "1 Year to 70 Years" }, "enrollment_count": null, "start_date": "1998-08", "completion_date": "2003-02", "has_results": false, "last_update_posted_date": "2011-11-30", "last_synced_at": "2026-10-15T12:15:37.331Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003887" }, { "nct_id": "NCT06799221", "title": "Expanded Access Program for OOS Obe-cel", "overall_status": "AVAILABLE", "study_type": "EXPANDED_ACCESS", "phases": [], "conditions": [ "Lymphoblastic Leukemia, Acute, Adult", "B Cell ALL" ], "interventions": [ { "name": "Out-of-specification obecabtagene autoleucel", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Autolus Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": null, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2026-02-27", "last_synced_at": "2026-10-15T12:15:37.331Z", "location_count": 32, "location_summary": "Gilbert, Arizona • Phoenix, Arizona • Duarte, California + 24 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06799221" }, { "nct_id": "NCT00840047", "title": "Methionine PET/CT Studies In Patients With Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Brain Tumors and/or Solid Tumors Including", "Brain Stem Glioma", "High Grade CNS Tumors", "Ependymoma", "Medulloblastoma", "Craniopharyngioma", "Low Grade CNS Tumors", "Hodgkin Lymphoma", "Non Hodgkin Lymphoma", "Ewing Sarcoma", "Osteosarcoma", "Rhabdomyosarcoma", "Neuroblastoma", "Other" ], "interventions": [ { "name": "Methionine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 503, "start_date": "2009-07-20", "completion_date": "2027-07-27", "has_results": false, "last_update_posted_date": "2026-06-17", "last_synced_at": "2026-10-15T12:15:37.331Z", "location_count": 1, "location_summary": "Memphis, Tennessee", "locations": [ { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00840047" }, { "nct_id": "NCT05144347", "title": "Study of XL114 in Subjects With Non-Hodgkin's Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-Hodgkin's Lymphoma (NHL)", "Activated B-Cell Type Diffuse Large B-Cell Lymphoma (ABC-DLBCL)", "Mantle Cell Lymphoma (MCL)", "Chronic Lymphocytic Leukemia (CLL)", "Small Lymphocytic Lymphoma (SLL)" ], "interventions": [ { "name": "XL114", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Exelixis", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2022-04-12", "completion_date": "2022-11-01", "has_results": false, "last_update_posted_date": "2023-07-11", "last_synced_at": "2026-10-15T12:15:37.331Z", "location_count": 4, "location_summary": "Tucson, Arizona • Indianapolis, Indiana • Pittsburgh, Pennsylvania + 1 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Spokane", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT05144347" }, { "nct_id": "NCT00361049", "title": "Donor Mesenchymal Stem Cell Infusion in Treating Patients With Acute or Chronic Graft-Versus-Host Disease After Undergoing a Donor Stem Cell Transplant", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "graft versus host disease prophylaxis/therapy", "type": "BIOLOGICAL" }, { "name": "fluorescence in situ hybridization", "type": "GENETIC" }, { "name": "immunoenzyme technique", "type": "OTHER" }, { "name": "immunohistochemistry staining method", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "in vitro-treated bone marrow transplantation", "type": "PROCEDURE" }, { "name": "management of therapy complications", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "GENETIC", "OTHER", "PROCEDURE" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 49, "start_date": "2004-09", "completion_date": "2010-11", "has_results": false, "last_update_posted_date": "2010-11-05", "last_synced_at": "2026-10-15T12:15:37.331Z", "location_count": 8, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00361049" } ] }